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Abstract
Studies have shown that vaccination with seven-valent pneumococcal conjugate vaccine (PCV7) results in a decline in nasopharyngeal
carriage of penicillin-resistant Streptococcus pneumoniae, in carriage of vaccine-type pneumococci, and in replacement by non-vaccine sero-
types. Vaccines can reduce pneumococcal resistance in vaccinated and unvaccinated populations by reducing the carriage of antibiotic-
resistant serotypes, which protects the vaccinated population and prevents spread of disease to others, and by decreasing antibiotic
resistance through overall reduction in antibiotic use. However, while reducing the level of vaccine serotypes and drug-resistant sero-
types in the nasopharynx, PCV7 also causes non-vaccine pneumococci replacement. The impact of serotype replacement on disease is
not clearly understood. Pelton et al. surveyed two communities shortly after the introduction of the PCV7 immunization programme
and found that while colonization with vaccine serotypes declined from 22% to 2% from 2000 to 2003, prevalence of non-vaccine sero-
types increased from 7% to 16%. Although penicillin-resistant colonizing S. pneumoniae isolates initially declined, penicillin-intermediate
isolates increased 2 years following PCV7 introduction. The change was primarily accounted for by an increase in penicillin-intermediate
serotype 19A. Serotype 19A is the only serotype not affected by PCV7 that is prevalent worldwide, clinically important, and highly
multidrug-resistant. A study by Hicks et al. established serotype 19A as the predominant post-PCV7 cause of invasive pneumococcal
disease (IPD) in children and the elderly. An increase in IPD rates caused by antibiotic-resistant serotype 19A isolates can also occur
without vaccination; reports indicate increases in regions characterized by extensive antibiotic use, underscoring the importance of
strategies to contain antibiotic resistance.
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Introduction
Streptococcus pneumoniae serotypes 6A, 6B, 9V, 14, 19A,
19F and 23F cause invasive pneumococcal disease (IPD) in
children. Clinically, all seven serotypes are associated
with resistance; serotypes 6B, 9V, 14, 19F and 23F
are considered to be the most highly antibiotic resistant.
The seven-valent pneumococcal conjugate vaccine (PCV7)
targets the seven serotypes that most often cause IPD in
children [1].
The effect of vaccine use on nasopharyngeal colonization
is important in relation to pathogen resistance, as pneumo-
coccal carriage is a critical source of horizontal spread of
pathogens within a community [2]. Studies have shown that
PCV7 alters the distribution of pneumococcal serotypes
in the nasopharynx and causes changes in serotype-specific
nasopharyngeal carriage and a decline in carriage of penicillin-
resistant S. pneumoniae [3]. Studies have demonstrated
a reduction in nasopharyngeal carriage of vaccine-type
pneumococci following conjugate vaccine administration
and replacement by non-vaccine serotypes, resulting in an
increased incidence of pneumococcal disease caused by
non-vaccine serotypes [1,3].
Laboratory-based data from the Active Bacterial Core
Surveillance Program in the USA from 1996 to 2004 were
used to analyse the effect of the pneumococcal conjugate
vaccine (PCV) on invasive disease caused by penicillin-resis-
tant strains [4]. An 81% decrease was observed, from 70.3
to 13.1 cases per 100 000, in the rate of invasive disease
caused by penicillin-non-susceptible pneumococci in children
aged <2 years—the target age for the use of PCV. An
increase in infections caused by serotypes not included in
PCV7 was also observed. The conclusion of this study was
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that there was a decrease in the rate of antibiotic-resistant
pneumococcal infections in young children after the intro-
duction of PCV7 [4].
Indirect Immunity
The introduction of new macrolides and their increased use
has led to a rise in the prevalence of macrolide resistance in
S. pneumoniae. An assessment of the emergence of macro-
lide-resistant invasive S. pneumoniae in Atlanta, Georgia,
before and after the licensing of PCV, recorded a decline in
the proportion of IPD in children aged <2 years, from a
mean of 28% in 1994–1999 to 10.6% in 2002 [5]. Also,
decreases in the incidence of IPD of 39% in the population
aged ‡65 years, 54% in adults aged 20–39 years and 25% in
adults aged 40–64 years were noted. Vaccine administration
was found to be a powerful strategy for reducing antibiotic
resistance in this community [5].
In a study by Kyaw et al. in the USA, in children aged
2–4 years, there was a significant reduction in the rate of
penicillin-non-susceptible IPD following administration of
PCV7 [4]. The rates of IPD caused by penicillin-non-suscep-
tible strains also decreased among persons aged ‡5 years, a
group that would not have received the conjugate vaccine,
and among adults aged ‡65 years [4]. This decrease in
penicillin-non-susceptible IPD among older children and
adults was due to a reduction in disease caused by vaccine
serotypes.
Day-care centres are the main form of out-of-home care
for preschool-aged children in the western world. Children
who attend day-care centres are at an increased risk of
infections, particularly respiratory infections. S. pneumoniae is
an important contributor to the increased incidence and
severity of respiratory infections in day-care centre attend-
ees. In a double-blind, randomized, controlled study con-
ducted in eight day-care centres in Israel, there was a
significant reduction in respiratory problems and use of anti-
biotics following administration of PCV [6]. The greatest
effect of the vaccine was on lower respiratory tract prob-
lems (47% risk reduction), followed by otitis media (20% risk
reduction) and upper respiratory tract infections (10% risk
reduction). This study clearly demonstrated the impact of
PCV administration on day-care centre attendees [6].
The impact of PCV7 in reducing antibiotic use in children
with acute otitis media was demonstrated in the Northern
California Kaiser Permanente clinical trial [7]. Children
received a primary series of vaccinations at 2, 4 and 6 months
of age, and a booster at 12–15 months. PCV7 reduced anti-
biotic prescriptions by 5.4% in the all-follow-up population
after starting dose 1, and by 5.7% in children after the pri-
mary series (per-protocol population). PCV7 reduced the
use of second-line antibiotics by 12.6% in the all-follow-up
population and by 13.3% in the per-protocol follow-up popu-
lation. From dose 1 to age 3.5 years, PCV7 eliminated 35
antibiotic prescriptions per 100 children vaccinated [7].
Vaccines can reduce pneumococcal resistance in both
the vaccinated population and their contacts in two ways:
by reducing the carriage of antibiotic-resistant serotypes,
and thereby providing protection against the disease and
preventing the spread of disease to others; and by
decreasing the promotion of antibiotic resistance through
reduced antibiotic use.
PCV not only reduces the level of vaccine serotypes in
the nasopharynx, while at the same time reducing the lev-
els of most of the resistant serotypes, but also results in
non-vaccine pneumococci replacement. This replacement in
the nasopharynx of children with non-vaccine pneumococci
is important, as it does not reduce the carriage rate but
merely changes the serotype. In a surveillance study,
Pelton et al. evaluated the pattern of pneumococcal naso-
pharyngeal carriage in two communities in Massachusetts
shortly after the introduction of the PCV7 immunization
programme in 2000 [3]. During the surveillance period
(2000–2003), nasopharyngeal colonization with vaccine sero-
types was found to decline from 22% to 2%. However,
the prevalence of non-vaccine serotypes increased from 7%
to 16% [3]. Although the evidence of serotype replace-
ment after PCV7 introduction is not questioned, what
remains to be understood is its relationship to replace-
ment disease. There is increasing evidence that replace-
ment disease occurs mostly in compromised hosts, e.g. the
elderly and people infected with the human immunodefi-
ciency virus. Moreover, adults may be more susceptible to
replacement disease.
Trends in non-susceptibility to antimicrobial agents
among colonizing pneumococcal isolates in adults were
examined before and after the introduction of PCV7 [8].
Following PCV7 introduction, the OR of developing resis-
tance to co-trimoxazole, tetracycline, ceftriaxone and
erythromycin was not increased; the calculated OR was
always <1.0. A dichotomy existed regarding penicillin resis-
tance. Following PCV7 introduction, a significant reduction
was observed (from 13% to 6%) in penicillin-resistant (MIC:
‡2 mg/L) colonizing S. pneumoniae isolates. In contrast, after
an initial decline (from 12% to 9%) 2 years after PCV7
introduction, the proportion of penicillin-intermediate
S. pneumoniae isolates (MIC: 0.1–1 mg/L) increased (to
19%). This change was primarily accounted for by an
increase in penicillin-intermediate serotype 19A [8].
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Documented Effect of PCV on Drug-
resistant S. pneumoniae (DRSP) Disease
and Carriage
It has been documented that the administration of PCV7 is
associated with a significant reduction in penicillin-resistant
S. pneumoniae (MIC: ‡2.0 mg/L), erythromycin-resistant S.
pneumoniae (MIC: ‡2.0 mg/L), and multidrug-resistant
S. pneumoniae (MDRSP, strain resistant to two or more
of the following antibiotics: penicillin, second-generation
cephalosporins, macrolides, tetracycline and trimethoprim–
sulfamethoxazole). The reduction in penicillin-intermediate-
resistant S. pneumoniae is not always obvious. An increase
may be seen through the emergence of such resistance
among replacing non-vaccine serotypes. An extensive effect
in contacts of the vaccinated population results in reduction
in DRSP disease and carriage, similar to that in the vacci-
nated population.
Threat of Increasing Prevalence of
Serotype 19a
Of the seven serotypes (6A, 6B, 9V, 14, 19A, 19F and 23F)
associated with resistance and multidrug resistance, sero-
type 19A is the only one that is prevalent worldwide, clini-
cally important, highly multidrug-resistant and not at all
affected by PCV7. In fact, the increase in incidence of IPD
caused by serotype 19A from 1998 to 2005 parallels an
increase in antibiotic resistance in this serotype [9]. Studies
on the age-specific incidence of IPD from 1998 to 2005 in
the USA showed a significant increase in serotype 19A prev-
alence in all age groups (Fig. 1) [9].
The Active Bacterial Core Surveillance Program also
showed an increase in the prevalence of penicillin-resistant
and non-susceptible serotype 19A [10]. In a separate study,
Hicks et al. showed that the predominant post-PCV7 non-
vaccine serotypes in children aged <5 years (19A, 15 and
33F) were also predominant in the adult population aged
‡65 years [1]. IPD due to non-vaccine serotypes 16F, 23A
and 35 was also seen. This study also revealed that the
rates of IPD due to non-vaccine serotypes increased incre-
mentally, most notably for serotype 19A [1]. The overall
annual rate of IPD among adults aged ‡65 years decreased
from 61.5 cases/100 000 population during 1998–1999 to
38.0 cases/100 000 population in 2004. This finding was
affected by a large decrease in the rate of disease due to
vaccine serotypes, from an average of 34.5 cases/100 000
population during the period 1998–1999 to 8.2 cases/
100 000 population in 2004 [1]. The difference in the rate
of disease due to non-vaccine serotypes between the
period 1998–1999 and 2004 in adults aged ‡65 years was
similar to the difference in children aged <5 years. This
study established serotype 19A as the predominant cause
of IPD in children and the elderly [1].
The percentage of penicillin-non-susceptible (intermediate
and resistant) serotype 19A isolates among children aged
<5 years increased from 63% during the period 1998–1999
to 74% in 2004 [1]. The percentage of erythromycin-non-
susceptible serotype 19A isolates increased significantly from
23% to 46% during the same comparison period. For adults
aged ‡65 years, the percentage of penicillin-non-susceptible
serotype 19A isolates decreased from 59% to 58%, whereas
the percentage of erythromycin-non-susceptible serotype 19A
isolates increased from 38% to 73% during the same compar-
ison period [1]. Between 1996 and 2004, the rate of disease
due to penicillin-non-susceptible serotype 19A increased
from 2.0 to 8.3 cases/100 000 population in children aged
<2 years, and from 1.3 to 2.2 cases/100 000 population in
adults aged ‡65 years [4].
The surveillance programme implemented in South Korea
involving all pneumococcal isolates obtained from children
aged <5 years since 1991 showed that serotype 19A iso-
lates were increasingly recognized among clinical isolates
before PCV7 was introduced in South Korea in November
2003 [11]. There was an 8% increase in serotype 19A iso-
lates between 1991 and 1997, and an 18% increase
between 1997 and 2003. This study showed that expansion
of multidrug-resistant sequence type 320 was responsible
for the increase in serotype 19A isolates [11]. A dramatic
increase in the rates of IPD caused by antibiotic-resistant
serotype 19A can occur without vaccination [11]. The role
of widespread antibiotic use and consequent antibiotic resis-
tance in facilitating the spread of serotype 19A is under-
scored by the fact that reports on the increase of disease
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FIG. 1. Age-specific incidence of serotype 19A invasive pneumococ-
cal disease, 1998–2005 [9]
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caused by serotype 19A are largely from regions character-
ized by extensive antibiotic use, frequent resistance, and
isolation of multidrug-resistant serotype 19A isolates (Dagan
R. Abstract presented at 18th ECCMID, Barcelona, Spain,
19–22 April 2008). PCV7 may have a role in the expansion
of serotype 19A, but it is too early to determine whether
this is indeed the case, especially in South Korea. Definitive
information on the contribution of PCV7 to the spread of
serotype 19A may come from studies in countries where
PCV7 has been introduced recently, but where antibiotic
use and resistance are less prevalent.
A study in Bedouin children in southern Israel was
conducted to examine the dynamics of serotype 19A isolates
in acute otitis media, where PCV7 has not yet been
introduced. The authors concluded that the increase in
serotype 19A isolates in these children originated from the
expansion of a specific multidrug-resistant clone, and this
increase in serotype 19A prevalence may not be related to
the introduction of PCV7 (Dagan R, Givon-Lavi N, Leibovitz
E, Porat N. Abstract presented at the 47th ICAAC, Chicago,
IL, 17–20 September 2007).
An increase in disease due to serotype 19A was reported
in regions with extensive use of antibiotics, frequent resis-
tance and multidrug-resistant serotype 19A in both the vacci-
nated and non-vaccinated populations. The role of antibiotics
in the increasing incidence of disease caused by serotype 19A
has been established. It is likely that PCV7 may have a role
in facilitating this increase in incidence; however, this is not
yet proven. The situation in countries that have recently
introduced PCV7, and in which antibiotic use and resistance
are less extensive, will probably shed more light on the
extent to which PCV7 contributes to increased disease
caused by serotype 19A.
Conclusions
Most clinically significant resistance, including MDRSP, is con-
fined to seven serotypes: 6A, 6B, 9V, 14, 19A, 19F and 23F.
Five of these serotypes are included in PCV7 (6B, 9V, 14,
19F and 23F). The incidence of serotype 6A, but not sero-
type 19A, may be reduced by PCV7.
Significant reductions in penicillin-resistant S. pneumoniae,
erythromycin-resistant S. pneumoniae and MDRSP have
been observed. Reductions in penicillin-intermediate S. pneu-
moniae are not always obvious, and increases may be seen
through the emergence of such resistance among replacing
non-vaccine serotypes. An extensive effect in contacts of
the vaccinated population (indirect immunity) results in
reduction of DRSP disease and carriage. Reduction in
antibiotic use remains critical to strategies to contain
antibiotic resistance. There is no effect on serotype 19A,
and increasing resistance within this serotype has resulted
in expansion of drug-resistant and multidrug-resistant
serotype 19A.
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